A pilot study of intraluminal brachytherapy using ¹²⁵I seed strand for locally advanced pancreatic ductal adenocarcinoma with obstructive jaundice

详细信息    查看全文

• 作者：MinJie Yang¹ ; ² ; ZhiPing Yan¹ ; ² ; JianJun Luo¹ ; ² ; QingXin Liu¹ ; ² ; Wen Zhang¹ ; ² ; JinQing Ma¹ ; ² ; ZiHan Zhang¹ ; ² ; TianZhu Yu¹ ; ² ; Qian Zhao¹ ; ² ; LingXiao Liu¹ ; ² ; ^{522623124@qq.com}
• 关键词：Brachytherapy ; Pancreatic ductal adenocarcinoma ; 125I seed ; Obstructive jaundice
• 刊名：Brachytherapy
• 出版年：2016
• 出版时间：November-December 2016
• 年：2016
• 卷：15
• 期：6
• 页码：859-864
• 全文大小：645 K
• 卷排序：15

文摘

To investigate the safety and feasibility of intraluminal brachytherapy using 125I seed strand for locally advanced pancreatic ductal adenocarcinoma with obstructive jaundice.Methods and MaterialsFrom January 2010 to February 2015, 18 consecutive patients diagnosed with locally advanced, nonmetastatic, inoperable pancreatic ductal adenocarcinoma with obstructive jaundice were enrolled and underwent intraluminal brachytherapy using 125I seed strand. Dose calculation was performed using a software. The procedure-related and radiation complications were assessed. Obstruction-free survival and overall survival were calculated using the Kaplan–Meier method.ResultsThe technique successful rate of 125I seed strand implantation was 100%. Successful bile drainage was achieved in all patients. The estimated mean accumulating dose (R = 5 mm, z = 0, 240 days) was 167.2 Gy, from 164.19 to 170.05 Gy. Two patients had adverse event of Grade 3, one of Grade 4. Stent dysfunction occurred in 1/18 (5.6%) patients. The mean and median obstruction-free survival time were 10.61 months (95% confidence interval [CI]: 7.04, 14.18) and 7.26 months (95% CI: 2.14, 12.38). The mean and median overall survival time were 11.91 months (95% CI: 7.39, 16.43) and 7.26 months (95% CI: 2.14, 12.38).ConclusionsIntraluminal brachytherapy using 125I seed strand may be consider as a safe treatment option for the therapy of locally advanced pancreatic duct adenocarcinoma complicated by obstructive jaundice with acceptable complication rates.